Transarterial Chemoembolization Outperforms Radioembolization in Early- and Intermediate-Stage Hepatocellular Carcinoma: A Multicenter Retrospective Study
Authors:
- Faisal M. SanaiFSFaisal M. Sanai
- Adnan AlzanbagiAAAdnan Alzanbagi
- Mohammed ArabiMAMohammed Arabi
- Sarah S. AlfawazSASarah S. Alfawaz
- Khalid I. BzeiziKBKhalid I. Bzeizi
- Mohammed AlmatrafiMAMohammed Almatrafi
- Abdulmalik M. AlsabbanAAAbdulmalik M. Alsabban
- Jameel BardesiJBJameel Bardesi
- Hamdan S. AlghamdiHAHamdan S. Alghamdi
- Mohamed ShawkatMSMohamed Shawkat
- Talal M. AlotaibiTATalal M. Alotaibi
- Khairat H. AlameerKAKhairat H. Alameer
Open Access
Abstract
Background: Transarterial radioembolization (TARE) with Yttrium-90 microspheres is an established therapy for unresectable hepatocellular carcinoma (HCC). However, its clinical efficacy compared to transarterial chemoembolization (TACE) remains unclear. Methods: We retrospectively reviewed 279 consecutive patients undergoing TARE (n = 104) or TACE (n = 175) at four tertiary centers. Patients with metastatic disease, locally advanced HCC, or Child–Pugh (CP) C were excluded. Data on treatment, adverse events, survival outcomes (median overall survival [mOS], and objective response rates [by modified Response Evaluation Criteria in Solid Tumors; mRECIST]) were collected. Results: The median follow-up of the cohort was 27 months (IQR 13–50), the mean age was 67.6 ± 10.1 years, and 207 (74.2%) were male. The cohort was balanced in age, performance status, CP class, and HCC etiology. Maximum tumor diameter was significantly larger in the TARE cohort compared to the TACE cohort (4.4 vs. 3.1 cm, p < 0.001), including within the BCLC 0/A (4.2 vs. 2.7 cm, p = 0.001) and BCLC B (5.0 vs. 4.0 cm, p = 0.049) subgroups. The mOS was longer with TACE (37 vs. 22 months; hazard ratio [HR] 1.65, 95% CI: 1.19–2.29, p = 0.002). In BCLC 0/A patients, TACE yielded longer mOS (60 vs. 25 months; HR 2.35, 95% CI: 1.17–4.69; p = 0.016). In BCLC B, mOS was longer with TACE (32 vs. 20 months), but was not statistically significant (HR 1.39, 95% CI: 0.96–2.03, p = 0.080). In BCLC 0/A, complete response rates were higher with TACE (43.2% vs. 34.3%, p = 0.012). Hepatic decompensation was more frequent with TARE- (26.0%) than with TACE-treated patients (13.7%, p = 0.010). Conclusions: TACE demonstrated superior survival outcomes over TARE, particularly in early-stage disease. These results advocate for a more nuanced selection of embolization therapies in these patients.Keywords
This publication has 32 references indexed in Scilit:
- Non selective beta-blockers prevent PHT-related complications occurrence in HCC patients with esophageal varices treated by TACEClinics and Research in Hepatology and Gastroenterology, 2024
- BCLC strategy for prognosis prediction and treatment recommendation: The 2022 updateJournal of Hepatology, 2021
- Comparison of Chemoembolization, Radioembolization, and Transarterial Ethanol Ablation for Huge Hepatocellular Carcinoma (≥ 10 cm) in Tumour Response and Long-Term Survival OutcomeCardioVascular and Interventional Radiology, 2021
- Yttrium‐90 Radioembolization for the Treatment of Solitary, Unresectable HCC: The LEGACY StudyHepatology, 2021
- Development of a prognostic score for recommended TACE candidates with hepatocellular carcinoma: A multicentre observational studyJournal of Hepatology, 2019
- Development of a prognostic score to predict response to Yttrium-90 radioembolization for hepatocellular carcinoma with portal vein invasionJournal of Hepatology, 2018
- Performance status in patients with hepatocellular carcinoma: Determinants, prognostic impact, and ability to improve the Barcelona Clinic Liver Cancer systemHepatology, 2012
- Survival after Yttrium-90 resin microsphere radioembolization of hepatocellular carcinoma across Barcelona clinic liver cancer stages: A European evaluationHepatology, 2011
- Therapeutic equivalence in survival for hepatic arterial chemoembolization and yttrium 90 microsphere treatments in unresectable hepatocellular carcinomaCancer, 2010
- Liver disease induced by radioembolization of liver tumorsCancer, 2008